Recombinant Cynomolgus/Rhesus Hepassocin/FGL1 Fc Protein, CF

Measured by its binding ability in a functional ELISA. When Recombinant Human LAG-3 Fc Chimera Protein (2319-L3) is immobilized at 2.50 μg/mL, 100 μL/well, Recombinant Cynomolgus Monkey/Rhesus Macaque Hepassocin/FGL1 Fc Chimera Protein (Catalog # 11176-HE) binds with an ED50 of 0.500-4.00 µg/mL.

2 μg/lane of Recombinant Cynomolgus Monkey/Rhesus Macaque Hepassocin/FGL1 Fc Chimera Protein (Catalog # 11176-HE) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 58-65 kDa and 120-130 kDa, respectively.

• Reactivity: Pm-Cm, RM
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Cynomolgus/Rhesus Hepassocin/FGL1 Fc Protein, CF Summary

• Additional Information: Fc Chimera
• Details of Functionality: Measured by its binding ability in a functional ELISA. When Recombinant Human LAG-3 Fc Chimera Protein (Catalog # 2319-L3) is immobilized at 2.50 μg/mL, 100 μL/well, Recombinant Cynomolgus Monkey/Rhesus Macaque Hepassocin/FGL1 Fc Chimera (Catalog # 11176-HE) binds with an ED 50 of 0.500-4.00 µg/mL.
• Source: Chinese Hamster Ovary cell line, CHO-derived Hepassocin/FGL1 protein

  MD

  Human IgG 1 Fc (Pro100-Lys330)

  IEGR

  Cynomolgus Monkey/Rhesus Macaque Hepassocin/FGL1 (Ala63-Ile348) Accession # XP_005562748.1

  N-terminus

  C-terminus

• Accession #: XP_005562748.1
• N-terminal Sequence: Met (of Fc)
• Structure / Form: Disulfide-linked homodimer
• Protein/Peptide Type: Recombinant Proteins
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 60 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 58-65 kDa, under reducing conditions.

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  12 months from date of receipt, -20 to -70 degreesC as supplied. 1 month, 2 to 8 degreesC under sterile conditions after reconstitution. 3 months, -20 to -70 degreesC under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS, NaCl and Glycerol with Trehalose.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 250 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Cynomolgus/Rhesus Hepassocin/FGL1 Fc Protein, CF

• FGL1
• fibrinogen-like 1
• fibrinogen-like protein 1
• Fibrinogen-like-protein 1
• FREP1
• Hepassocin
• hepatocellular carcinoma-related sequence
• Hepatocyte-derived fibrinogen-related protein 1
• HFREP-1
• HFREP1MGC12455
• HP-041
• LFIRE1
• LFIRE-1
• Liver fibrinogen-related protein 1

Background

Hepassocin, also known as Hepatocyte-derived fibrinogen-related protein 1 (HFREP-1) and Fibrinogen-Like Protein 1 (FGL1) (1), is a liver-specific secreted protein belonging to the fibrinogen superfamily whose members share a fibrinogen domain at their C-termini (2). Human Hepassocin/FGL1 is a secreted homodimer consisting of 312 amino acids (aa) with a 22 aa signal sequence and a 290 aa mature protein (3). Cynomolgus monkey shares 100% and 96.5% amino acid identity with rhesus macaque and human Hepassocin/FGL1, respectively. Hepassocin/FGL1 binds LAG-3 through its fibrinogen-like domain independently of MHC class II (4). Hepassocin/FGL1 inhibits antigen-specific T cell activation, with its elevated presence in plasma of cancer patients indicating poor prognoses (4). Other than this role in cancer progression, Hepassocin/FGL1 also has restorative function for liver cells. It is upregulated during liver regeneration following partial hepatectomy (5), and stimulates proliferation of hepatocytes in vivo and improves prognoses with fulminant hepatic failure in rats (6). Its expression is regulated in Hep G2 cells by interleukin-6 (IL-6) and is found in the serum in both bound and unbound states as an acute phase reactant (7).

1. Yamamoto, T. et al. (1993) Biochem. Biophys. Res. Commun. 2:681.
2. Zhang, S.M. et al. (2008) Innate Immun. 14:175.
3. Hara, H. et al. (2001) Biochim. Biophys. Acta. 1520:45.
4. Wang, J. et al. (2019) Cell. 176:334.
5. Yu, HT. et al. (2009) J. Biol. Chem. 284:13335.
6. Li, C.Y. et al. (2010) Gut. 59:817.
7. Liu, Z. and C. Ukomadu. (2008) Biochem. Briophys. Res. Commun. 365:729.

Bioinformatics

• Uniprot:
  • XP_005562748.1()